Artiva Biotherapeutics (NASDAQ:ARTV) Director Buys $135,464.94 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock in a transaction that occurred on Friday, July 10th. The stock was acquired at an average cost of $8.97 per share, with a total value of $135,464.94. Following the purchase, the director directly owned 16,811,021 shares of the company’s stock, valued at $150,794,858.37. This represents a 0.09% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. acquired 548,580 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. bought 479,039 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $9.04 on Friday. The firm has a market cap of $223.47 million, a price-to-earnings ratio of -2.55 and a beta of 2.18. The firm has a 50-day simple moving average of $8.89 and a two-hundred day simple moving average of $7.10. Artiva Biotherapeutics, Inc. has a one year low of $2.22 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ARTV. Wedbush upped their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Needham & Company LLC reissued a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARTV. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $41,000. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the period. Bridgeway Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 2nd quarter valued at approximately $53,000. Qube Research & Technologies Ltd purchased a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at $58,000. Finally, Jane Street Group LLC purchased a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at $67,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.